| abstract |
The present invention relates to chimeric antigen receptors (CARs) comprising an antigen binding domain that specifically binds to melanoma cells, polynucleotides encoding such CARs, and vectors comprising such polynucleotides. The invention further relates to engineered cells comprising the polynucleotides and/or transduced by the viral vectors, and compositions comprising a plurality of engineered T cells. The invention also relates to methods of making such engineered T cells and compositions, and to the use of such engineered T cells and compositions in the treatment of melanoma. |